AGORANOV Founded 2000
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 318
Average round size
info
The average size of a deal this fund participated in
$83K
Portfolio companies 317
Rounds per year 15.10
Lead investments 37
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.01
Exits 30
Areas of investment
Artificial Intelligence
Biotechnology
Health Care
Industrial
Software
Summary

AGORANOV is the famous Corporate Investor, which was founded in 2000. The fund was located in Europe if to be more exact in France. The main office of represented Corporate Investor is situated in the Paris.

Among the various public portfolio startups of the fund, we may underline Criteo, Doctolib, Ynsect The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the most popular fund investment industries, there are Health Care, Medical Device. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund.

Besides them, we counted 1 critical employee of this fund in our database.

The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the AGORANOV, startups are often financed by Wilco, NUMA, Bpifrance. The meaningful sponsors for the fund in investment in the same round are The Family, Sowefund, Kurma Partners. In the next rounds fund is usually obtained by XAnge, CapDecisif, Kima Ventures.

The top amount of exits for fund were in 2018. Speaking about the real fund results, this Corporate Investor is 19 percentage points less often commits exit comparing to other organizations. This AGORANOV works on 19 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Deals in the range of 1 - 5 millions dollars are the general things for fund. The fund is constantly included in 13-24 deals per year.

Read more
Notable deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
Castor
Clinical Trials
Health Care
Medical
Pharmaceutical
SaaS
Software
Therapeutics
Non-equity Assistance
01 Dec 2020 France, Paris
Circul'Egg
Food and Beverage
Food Processing
Recycling
01 Nov 2020 France, Paris
Fairbrics
01 Oct 2020 France, " France"}
Monk.ai
Artificial Intelligence
Auto Insurance
Computer Vision
Insurance
Sharing Economy
Software
Non-equity Assistance
01 Sep 2020 France, Paris
SportsDynamics
Data Visualization
Information Technology
Predictive Analytics
Soccer
Software
Sports
Non-equity Assistance
01 Aug 2020 France, Paris
Terality
Artificial Intelligence
Machine Learning
Software
Non-equity Assistance
01 Jul 2020 France, Paris
Lynceus
Machine Learning
Manufacturing
Predictive Analytics
Quality Assurance
Software
Non-equity Assistance
01 Jun 2020 France, Paris
Alice & Bob
Information Services
Information Technology
Non-equity Assistance
01 Apr 2020 France, Paris
01 Mar 2020
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent AGORANOV?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: